IgIQ: Your Single Source for Ig Solutions

Welcome to IgIQ, a comprehensive resource center for people who depend on CSL Behring's immune globulin (Ig) therapies.

IgIQ gathers many Ig resources under one roof, making it easy to get the guidance and support you need with a single phone call. Our friendly and knowledgeable staff can:

  • Answer general (non-medical) questions
  • Provide helpful resources
  • Enroll you in peer support and financial assistance programs
  • Answer questions related to insurance coverage

Have Questions?

To get the guidance and support you need,
Call 1-877-355-IGIQ (4447)
Monday–Friday, 8 AM to 8 PM ET

Need help paying for Hizentra?

Hizentra Co-Pay Relief Help for new and existing Hizentra patients
The Hizentra Co-Pay Relief program helps eligible patients afford their therapy by helping with monthly out-of-pocket expenses for Hizentra (up to $5,000 for one year, with no monthly cap*).

To be eligible:

  • Prescription must be for primary immunodeficiency diagnosis
  • Patients must be at least 2 years of age
  • Patient must be receiving Hizentra through a specialty pharmacy or physician office
  • It is recommended that the patient use a Specialty Pharmacy provider that is in-network with the patient's current plan
  • Patient must express financial need
  • Patient must have coverage for the product under a private US insurance plan. Not valid for prescriptions eligible for reimbursement by any federal or state healthcare program, such as Medicare, Medicare advantage plans, Medicaid, PCIP, Champus, TriCare, Veterans Administration (VA), or any other state or federal program
  • Patients whose insurance policy prohibits co-pay assistance are not eligible
  • This program is subject to change or discontinuation by CSL Behring at any time, for any reason, and with or without prior notice
  • Hizentra Co-Pay Relief program is administered by Medmonk Inc., terms and conditions apply

It’s easy
Enrollment happens seamlessly at the Specialty Pharmacy. Patients interested in receiving co-pay assistance, must contact their Specialty Pharmacy, express their need for financial assistance and ask the pharmacy to enroll them by requesting Hizentra Copay Assistance via Medmonk. Patients can contact CSL Behring's IgIQ* Resource Center at 1-877-355-IGIQ (4447) or visit www.Hizentra.com/copay for additional information.

*Other terms and conditions may apply.

This program applies to product costs only; however, assistance for infusion-related costs may be available through a non-profit patient support organization. Contact IgIQ to learn more.

Prior to enrolling in this CSL Behring program, participants are responsible for checking with their insurance carrier to confirm that their participation is not inconsistent with their insurance carrier’s requirements.

Protect yourself from a lapse in coverage.

CSL Behring Assurance CSL Behring understands the stress and hardship caused by a lapse in health insurance. CSL Behring AssuranceSM is designed to help ensure that people who rely on our Ig therapies can continue to receive treatment even if they experience a lapse in third-party, private health insurance.

Benefits for Patients
Patients earn CSL Behring Assurance points for every month of continuous Ig product use. The points are redeemable for Ig therapy in the event you lose insurance coverage. Points are issued based on product use from the date that enrollment eligibility is approved, so it’s important to enroll as soon as possible.

EASY TO ENROLL:

  • Enrollment is free
  • Simply contact your IgIQ Care Coordinator

EASY TO USE:

  • Earn a point for every consecutive month of product use.
  • Redeem 3 points for a one‐month supply of your CSL Behring product.
  • If you suffer a lapse in your insurance simply contact a CSL Behring Assurance Care Coordinator and we will take care of the rest.

Certain limitations apply—see program Terms and Conditions for additional information.

Ensure access to treatment during difficult times.

CSL Behring Biotherapies for Life Access to treatment during difficult times
Periodically, patients with chronic illnesses are faced with difficult insurance situations that may prevent access to life-sustaining therapies.

The CSL Behring Patient Assistance ProgramSM provides Hizentra free of charge if you do not have prescription drug insurance or have been denied coverage by your insurance company and meet specific financial and medical criteria.

  • Qualified patients may receive up to a 3-month supply of their Ig product
  • At the end of 3 months, the patient’s eligibility is re-evaluated for continued participation in the program, if needed
  • Emergency needs are addressed under a separate process when a call is received within 24 hours of the emergency



Your Comprehensive Library of Resources

We know how overwhelming living with PI can be. So we've assembled a comprehensive library of resources to help you throughout your journey.

Expand

Important Safety Information

Immune Globulin Subcutaneous (Human), Hizentra®, treats various forms of primary immunodeficiency (PI) in patients age 2 and over.

WARNING: Thrombosis (blood clotting) can occur with immune globulin products, including Hizentra. Risk factors can include: advanced age, prolonged immobilization, a history of blood clotting or hyperviscosity (blood thickness), use of estrogens, installed vascular catheters, and cardiovascular risk factors.

If you are at high risk of thrombosis, your doctor will prescribe Hizentra at the minimum dose and infusion rate practicable and will monitor you for signs of thrombosis and hyperviscosity. Always drink sufficient fluids before administration.

Tell your doctor if you have had a serious reaction to other immune globulin medicines or have been told you also have a deficiency of the immunoglobulin called IgA, as you might not be able to take Hizentra. You should not take Hizentra if you know you have hyperprolinemia (too much proline in your blood).

Infuse Hizentra under your skin only; do not inject into a blood vessel.

Allergic reactions can occur with Hizentra. If your doctor suspects you are having a bad allergic reaction or are going into shock, treatment will be discontinued. Immediately tell your doctor or go to the emergency room if you have signs of such a reaction, including hives, trouble breathing, wheezing, dizziness, or fainting.

Tell your doctor about any side effects that concern you. Immediately report symptoms that could indicate a blood clot, including pain and/or swelling of an arm or leg, with warmth over affected area; discoloration in arm or leg; unexplained shortness of breath; chest pain or discomfort that worsens with deep breathing; unexplained rapid pulse; and numbness or weakness on one side of the body. Your doctor will also monitor symptoms that could indicate hemolysis (destruction of red blood cells), and other potentially serious reactions that have been seen with Ig treatment, including aseptic meningitis syndrome (brain swelling); kidney problems; and transfusion-related acute lung injury.

The most common drug-related adverse reactions in the clinical trial for Hizentra were swelling, pain, redness, heat or itching at the site of injection; headache; back pain; diarrhea; tiredness; cough; rash; itching; nausea and vomiting.

Hizentra is made from components of human blood. The risk of transmission of infectious agents, including viruses and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent, cannot be completely eliminated.

Before being treated with Hizentra, inform your doctor if you are pregnant, nursing or plan to become pregnant. Vaccines (such as measles, mumps and rubella) might not work well if you are using Hizentra. Before receiving any vaccine, tell the healthcare professional you are being treated with Hizentra.

Please see full prescribing information for Hizentra, including boxed warning and the patient product information.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Collapse
CSL Behring
Hizentra is manufactured by CSL Behring AG and distributed by CSL Behring LLC.
Hizentra® is a registered trademark of CSL Behring AG.
IgIQ® is a registered trademark of CSL Behring LLC.
CSL Behring AssuranceSM and CSL Behring Patient Assistance ProgramSM are service marks of CSL Behring LLC.
© 2017 CSL Behring LLC. The product information presented on this site is intended for US residents only. HIZ/09-12-0016k(1) 9/2015